Flagship launches Ring with $50M, new gene therapy vectors

Ring aims to solve gene therapy’s biggest problems: immunogenicity, tissue access and genomic integration

Ring Therapeutics, the latest company to emerge from Flagship Pioneering, has a gene therapy platform that it thinks will solve the biggest problems with the modality: immunogenicity, tissue access and genomic integration.

With a $50 million initial investment, the company is creating a new type of viral vector based on a family of commensal human viruses dubbed anelloviruses, which naturally exist in

Read the full 618 word article

User Sign In